With over 6 million possible combinations, it is difficult to come up with the best treatment for each patient. The phase III DURATION-8 trial may help you to decide.
Read More »Adding an SGLT-2 Inhibitor For Type 1 Diabetes
DEPICT-2 study of more than 800 people worldwide indicates positive results without added risk of severe hypoglycemia, but slight increase in DKA events.
Read More »Sotagliflozin (SGLT-2) in Conjunction with Insulin for T1D Reduces Average Glucose Levels
One-year results of North American inTandem1 study show decreased HbA1c levels and lower risk of severe hypoglycemia.
Read More »Amazing Outcomes with Combination Therapy of GLP-1 Receptor Agonist and SGLT2 Inhibitors
The different mechanisms of action of these two drugs make them an excellent combination in the treatment of patients with type 2 diabetes mellitus (T2DM).
Read More »Sotagliflozin (Zynquista): A Novel SGLT Medication
Sotagliflozin to be reviewed by the FDA as possible oral adjunct for people with insulin-treated type 1 diabetes.
Read More »Risk of Euglycemic Diabetic Ketoacidosis After Initiation of an SGLT-2 Inhibitor
Detection of euglycemic ketoacidosis could be a challenge for physicians since this condition can mask an underlying diabetic ketoacidosis.
Read More »Do SGLT2 Inhibitors Increase the Risk of Acute Kidney Injury?
2016 FDA warning conflicts with recent evidence showing no increased risk following use of treatment.
Read More »Addition of SGLT2 Inhibitor when Glycemic Control Cannot be Attained with Insulin Alone
Benefits of SGLT2 inhibitors in patients treated with insulin.
Read More »Canagliflozin Vs. Dapagliflozin in Type 2 Diabetes
First real-world study comparing SGLT2i therapies also showed patients taking INVOKANA 300 mg significantly less likely to discontinue treatment or switch to another diabetes medicine.
Read More »Which Diabetes Treatment Is Most Effective In Keeping Your Patients Alive?
SGLT-2 inhibitors, GLP-1 agonists, and DPP-4 inhibitors compared in reducing mortality and cardiovascular events in patients with type 2.
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.